24 related articles for article (PubMed ID: 32981512)
1. Synthesis and Characterization of a New Class of Chromene-Azo Sulfonamide Hybrids as Promising Anticancer Candidates with the Exploration of Their EGFR,
Alblewi FF; Alsehli MH; Hritani ZM; Eskandrani A; Alsaedi WH; Alawad MO; Elhenawy AA; Ahmed HY; El-Gaby MSA; Afifi TH; Okasha RM
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069037
[TBL] [Abstract][Full Text] [Related]
2. A New Family of Benzo[
Abd-El-Aziz AS; Alsaggaf A; Assirey E; Naqvi A; Okasha RM; Afifi TH; Hagar M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802075
[TBL] [Abstract][Full Text] [Related]
3. 4H-Chromene-based anticancer agents towards multi-drug resistant HL60/MX2 human leukemia: SAR at the 4th and 6th positions.
Puppala M; Zhao X; Casemore D; Zhou B; Aridoss G; Narayanapillai S; Xing C
Bioorg Med Chem; 2016 Mar; 24(6):1292-7. PubMed ID: 26867486
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Characterization and Antimicrobial and Anticancer Evaluations of Some Novel Heteroannulated Difuro[3,2-
Alshaye NA; Ibrahim MA; Badran AS
Molecules; 2024 May; 29(10):. PubMed ID: 38792180
[TBL] [Abstract][Full Text] [Related]
5. A synthetic study on antiviral and antioxidative chromene derivative.
Mori J; Iwashima M; Takeuchi M; Saito H
Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):391-6. PubMed ID: 16508200
[TBL] [Abstract][Full Text] [Related]
6. Novel benzo chromene derivatives: design, synthesis, molecular docking, cell cycle arrest, and apoptosis induction in human acute myeloid leukemia HL-60 cells.
Abd El-Hameed RH; Mohamed MS; Awad SM; Hassan BB; Khodair MAE; Mansour YE
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):405-422. PubMed ID: 36458403
[TBL] [Abstract][Full Text] [Related]
7. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
8. Chromenes - A Novel Class of Heterocyclic Compounds: Recent Advancements and Future Directions.
Chaudhary A; Singh K; Verma N; Kumar S; Kumar D; Sharma PP
Mini Rev Med Chem; 2022; 22(21):2736-2751. PubMed ID: 35362382
[TBL] [Abstract][Full Text] [Related]
9. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
Abdelatef SA; El-Saadi MT; Amin NH; Abdelazeem AH; Omar HA; Abdellatif KRA
Eur J Med Chem; 2018 Apr; 150():567-578. PubMed ID: 29549841
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA
Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Evaluation of Cytotoxic Activity of Certain Benzo[h]chromene Derivatives.
Awad SM; Mohamed MS; Khodair MAE; El-Hameed RHA
Anticancer Agents Med Chem; 2021; 21(8):963-986. PubMed ID: 32981512
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
